BioSpace News Archive

A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update.

VitaTek, the only vertically integrated medical device incubator, accelerator, and manufacturer, is thrilled to announce the launch of a Series A Funding round with the goal to raise $50 million.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 60,000 shares of its common stock to one new employee.

Sequana Medical NV announces that the first two patients from the non-randomized cohort of the MOJAVE study were successfully treated with DSR 2.0, including safe and effective maintenance of euvolemia without the need for loop diuretics, considerable benefit in their cardiorenal status and a dramatic improvement in their diuretic response and loop diuretic requirements.

Sensorion is pleased to announce its participation, in-person, in the European Society of Gene & Cell Therapy conference, taking place on October 24-27, 2023, in Brussels, Belgium.

EvolveImmune Therapeutics will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California.

LSL Pharma Group Inc. announced that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC, a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP for the treatment of newborns in U.S. hospitals.